A Randomized, Placebo-controlled, Double-masked, Multi-center, Dose-ranging Study to Evaluate the Safety, and Efficacy of UNR844 in Subjects With Presbyopia
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Lipoic acid choline ester (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Acronyms READER
- Sponsors Novartis Pharmaceuticals
- 23 Jan 2023 Status changed from completed to discontinued.
- 03 Nov 2022 Status changed from active, no longer recruiting to completed.
- 14 Sep 2022 Planned End Date changed from 10 Apr 2023 to 27 Sep 2022.